Table 2 Key driver gene mutation rate in cancer patients with POLE or POLD1 damaging variants.
Gene Name | POLE Dam Var | Gene Name | POLE Exo Dam Var | Gene Name | POLD1 Dam Var |
|---|---|---|---|---|---|
PIK3CA | 51.9% | APC | 100.0% | PIK3CA | 35.7% |
TP53 | 48.2% | ROS1 | 100.0% | TP53 | 35.7% |
APC | 33.3% | MLH3 | 85.7% | APC | 28.6% |
KRAS | 33.3% | PIK3CA | 71.4% | KRAS | 28.6% |
CTNNB1 | 29.6% | FBXW7 | 71.4% | CHD4 | 28.6% |
EGFR | 29.6% | ATM | 71.4% | SMARCA4 | 28.6% |
FBXW7 | 29.6% | KIT | 71.4% | MSH3 | 21.4% |
MLH3 | 25.9% | MSH6 | 71.4% | ARID1A | 21.4% |
ROS1 | 25.9% | PDGFRA | 71.4% | MLH3 | 14.3% |
ATM | 22.2% | RB1 | 71.4% | FBXW7 | 14.3% |
KIT | 22.2% | BRCA2 | 71.4% | ATM | 14.3% |
MSH6 | 22.2% | MSH3 | 71.4% | BRCA2 | 14.3% |
PDGFRA | 22.2% | PMS1 | 71.4% | CTNNB1 | 14.3% |
RB1 | 22.2% | KRAS | 57.1% | ALK | 14.3% |
SMAD2 | 22.2% | CTNNB1 | 57.1% | TGFBR2 | 14.3% |
ALK | 18.5% | SMAD2 | 57.1% | EGFR | 14.3% |
ARID1A | 18.5% | CHD4 | 57.1% | GNAS | 14.3% |
BRCA2 | 18.5% | SMAD4 | 57.1% | PMS2 | 14.3% |
CHD4 | 18.5% | TP53 | 42.9% | ||
HGF | 18.5% | ALK | 42.9% | ||
MLH1 | 18.5% | HGF | 42.9% | ||
MSH3 | 18.5% | MLH1 | 42.9% | ||
PMS1 | 18.5% | TGFBR2 | 42.9% | ||
TGFBR2 | 18.5% | BRCA1 | 42.9% | ||
BRCA1 | 14.8% | MET | 42.9% | ||
MET | 14.8% | NTRK1 | 42.9% | ||
NTRK1 | 14.8% | FGFR1 | 42.9% | ||
NTRK3 | 14.8% | MSH2 | 42.9% | ||
SMAD4 | 14.8% | EGFR | 28.6% | ||
SMARCA4 | 14.8% | ARID1A | 28.6% | ||
FGFR1 | 11.1% | NTRK3 | 28.6% | ||
FGFR2 | 11.1% | SMARCA4 | 28.6% | ||
GNAS | 11.1% | FGFR2 | 28.6% | ||
MSH2 | 11.1% | GNAS | 28.6% | ||
RET | 14.3% | ||||
BRAF | 14.3% | ||||
NRAS | 14.3% | ||||
PMS2 | 14.3% |
